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Abstract
Introduction: Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast 
cancer. However, only a small portion of patients have a complete response to paclitaxel-based chemotherapy, and 
many patients are resistant. Strategies that increase sensitivity and limit resistance to paclitaxel would be of clinical use, 
especially for patients with triple-negative breast cancer (TNBC).
Methods: We generated a gene set from overlay of the druggable genome and a collection of genomically 
deregulated gene transcripts in breast cancer. We used loss-of-function RNA interference (RNAi) to identify gene 
products in this set that, when targeted, increase paclitaxel sensitivity. Pharmacological agents that targeted the top 
scoring hits/genes from our RNAi screens were used in combination with paclitaxel, and the effects on the growth of 
various breast cancer cell lines were determined.
Results: RNAi screens performed herein were validated by identification of genes in pathways that, when previously 
targeted, enhanced paclitaxel sensitivity in the pre-clinical and clinical settings. When chemical inhibitors, CCT007093 
and mithramycin, against two top hits in our screen, PPMID and SP1, respectively, were used in combination with 
paclitaxel, we observed synergistic growth inhibition in both 2D and 3D breast cancer cell cultures. The transforming 
growth factor beta (TGFβ) receptor inhibitor, LY2109761, that targets the signaling pathway of another top scoring hit, 
TGFβ1, was synergistic with paclitaxel when used in combination on select breast cancer cell lines grown in 3D culture. 
We also determined the relative paclitaxel sensitivity of 22 TNBC cell lines and identified 18 drug-sensitive and four 
drug-resistant cell lines. Of significance, we found that both CCT007093 and mithramycin, when used in combination 
with paclitaxel, resulted in synergistic inhibition of the four paclitaxel-resistant TNBC cell lines.
Conclusions: RNAi screening can identify druggable targets and novel drug combinations that can sensitize breast 
cancer cells to paclitaxel. This genomic-based approach can be applied to a multitude of tumor-derived cell lines and 
drug treatments to generate requisite pre-clinical data for new drug combination therapies to pursue in clinical 
investigations.
Introduction
Chemotherapy regimens containing taxanes, including
docetaxel and paclitaxel, have well-established benefits in
breast cancer [1,2]. Despite improvement in the response
rates with use of taxane-based drug combinations versus
single agent taxanes, most patients do not have a com-
plete response to treatment [3-6]. A partial response or
resistance to paclitaxel is a major limiting factor in the
successful treatment of breast cancer. Improving taxane-
based chemotherapy regimens through novel drug com-
binations is therefore of clinical interest. Patients with
tumors that lack expression of estrogen receptor (ER),
progesterone receptor (PR), and HER2 amplification (tri-
ple-negative breast cancer, TNBC) are not candidates for
currently available FDA-approved, targeted therapies.
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More efficacious combination chemotherapy is needed
for these patients.
Due to its extensive use in breast cancer and other
tumor types and the frequency of acquired resistance,
mechanisms of taxane resistance have been investigated
[7-9]. Some mechanisms identified to date include muta-
tions of the β-tubulin gene [10,11], expression of the
tubulin binding protein tau [12], expression of ER [13,14],
HER2 [15,16], BRCA1 [17,18], and p-glycoprotein/MDR1
[19-21], among others [8,9]. Genomic studies have also
been used for predicting response to both paclitaxel and
related compound docetaxel [3,5,6,22,23], but few if any
genes amongst these studies overlap or have been con-
firmed as reliable markers or predictors of response.
Despite these studies, novel therapeutic combinations
with paclitaxel are being tested in clinical trials, especially
in patients with advanced disease or those without clini-
cally proven therapeutic targets such as TNBC [24-26].
Identification of gene products that when pharmacologi-
cally inhibited enhance paclitaxel sensitivity may lead to
improved response rates and reduced resistance.
The advent of RNA interference (RNAi) for gene silenc-
ing allows for systematic gene and/or pathway analysis in
tumor cells and an ability to uncover novel gene functions
and pathways that cannot always be identified by ectopic
gene expression. Several RNAi studies performed in
human tumor cell lines using synthetic small interfering
RNAs (siRNAs) or vector-based short hairpin RNAs
(shRNAs) targeting defined gene families or genome-
wide libraries have identified modulators of drug sensitiv-
ity [27-33]. These studies have unveiled novel pathways
and molecules for therapeutic targeting in various tumor
types and there is a great need to translate this informa-
tion for clinical utility.
Genomic tumor profiling has provided us with impor-
tant insights to mechanisms of tumorigenesis and trans-
lational data for clinical advances. Relative to some
cancer types, there is tremendous genomic information
available for breast cancers, which includes tumor DNA
copy number [34-38], DNA sequence and mutations [39-
44], gene expression and protein profiles [45,46], as well
as epigenetics [47,48] and microRNAs [49,50]. In the cur-
rent study, we performed genetic loss-of-function RNAi
screens to identify druggable targets involved in pacli-
taxel sensitivity. In our screens, we used a gene set that is
comprised of the overlay of a druggable genome library
with a set of genes considered to be deregulated in breast
cancer (from genomic studies of human breast cancers
and cell lines [37,38]). Specific pharmacological inhibi-
tors of the top scoring hits from our screens were used in
combination with paclitaxel and the ability of the chemi-
cals to enhance the growth inhibitory activity of pacli-
taxel on breast tumor-derived cell lines was analyzed. We
further tested these novel paclitaxel drug combinations
on four paclitaxel-resistant TNBC cell lines and for select
inhibitors showed synergistic drug activity. New findings
presented in this study show the feasibility of loss-of-
function screening to provide biological relevance for
genomic discoveries and to identify drug combinations to
improve current taxane-based drug treatments in pre-
clinical models for breast cancer.
Materials and methods
Reagents and resources
Paclitaxel, CCT007093, and mithramycin A (Sigma-
Aldrich, St. Louis, MO, USA) were prepared in DMSO at
a stock concentration of 0.1 mM, 5 mM, and 0.9 mM,
respectively. LY2109761 was kindly provided by Jonathan
Yingling, Lilly Research Laboratories, Indianapolis, IN,
USA and prepared in DMSO at 10 mM stock concentra-
tion. The panel of candidate genes used in the shRNA
screen was generated from overlay of a list of 1,778
genomically deregulated gene transcripts whose levels
significantly correlated with genome copy number in
breast cancer [37,38] and a druggable genome list com-
piled from two sources (Open Biosystems, Huntsville,
AL, USA and Qiagen, Valencia, CA, USA). Pharmacolog-
ical agents were identified using several drug databases
including DrugBank, Therapeutic Target Database, Com-
parative Toxicogenomics Database, and Ingenuity Path-
way Analysis.
Cell culture
HeLa and MCF-7 cells were purchased from American
Tissue Cell Culture (ATCC, Manassas, VA, USA) and cul-
tured in Dulbecco's modified Eagle's medium (DMEM,
Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum, and 1% penicillin-streptomycin. All
TNBC cell lines were purchased from ATCC or Deutsche
Sammlung von Mikroorganismen und Zellkulturen
GmbH (DSMZ, Braunschweig, Germany) and cultured as
described (Additional File 1). All cells were cultured at
37°C with 5% CO2 and tested routinely for mycoplasma,
using the MycoAlert Detection Kit (Cambrex, Rockland,
ME, USA).
shRNA and siRNA screens
HeLa cells were plated at 20,000 cells per well (96-well
plate) and 24 h later transfected with a subset of the
human genome pGIPZ shRNAmir plasmid library (n =
1,078) (Open Biosystems), as provided by the Functional
Genomics Shared Resource at Vanderbilt University in a
one clone per well format. The next day, cells were split
1:6 into 96-well plates, allowed to attach overnight, and
three plates were treated with vehicle control (DMSO)
and three were treated with 5 nM paclitaxel for 24 h. Cells
were washed, replaced with fresh media and incubated
for an additional 72 to 96 h. Alamar Blue (Invitrogen), aBauer et al. Breast Cancer Research 2010, 12:R41
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dye used to detect metabolic activity in cells, was used to
assay for cell viability and to identify genes that alter
paclitaxel sensitivity. To identify gene targets that pro-
mote paclitaxel sensitivity or resistance, we generated a
sensitivity index (SI) score for each shRNA obtained from
replicate experiments after drug treatment [32]. The SI
score accounts for both the individual effect of shRNAs
and the effect of drug on cell viability (see next section for
description of the statistical methodology). Data from
each plate were normalized to non-silencing (NS) shRNA
controls that do not target any human gene, to account
for plate-to-plate variability and to control for the effects
of shRNA transfection. For the siRNA screen, two inde-
pendent siRNAs were designed for each gene and ran-
domly distributed in a 96-well plate. MDA-MB-231 and
MDA-MB-468 cells were reverse-transfected with siR-
NAs complexed with lipid reagent for 48 h and subse-
quently split into four replicate plates. Cells were treated
and measured for viability in a similar fashion as above.
Transfections (that is, experiments) were performed in
triplicate to allow for assessment of variation of expres-
sion data in statistical analysis.
Statistical analysis
Median centered global normalization was performed
across all shRNA and siRNA plates by using the NS con-
trols in each plate. The SI score was calculated for each of
the shRNAs and siRNAs by estimating the difference
between the expected and observed combined effects of
shRNAs or siRNAs and paclitaxel on cell viability, as pre-
viously described [32]. The SI scores range from -1 to 1.
Positive SI scores indicate sensitizing effects and negative
SI scores indicate antagonizing effects.
A bootstrap algorithm was used to estimate the vari-
ability of the mean SI level for each gene with > 3 shRNAs
by randomly sampled from all shRNAs of that gene with
replacement. The corresponding 95% percentile boot-
strap confidence interval was calculated for each gene.
Genes were taken as hits if they had a mean bootstrap in
the upper quartile cutoff SI > 0.078 and the lower bound
of 95% confidence interval > 0. The results of a small sim-
ulation study we carried out show that the bootstrap dis-
tribution from a very small number of shRNAs (≤3 per
gene) is not reliable. Therefore, the mean SI value was
calculated for the genes with ≤3 shRNAs. A more strin-
gent cutoff (SI > 0.15) was used for hit selection among
these genes. For the siRNA screen, the SI value was calcu-
lated by averaging the two siRNAs for each gene after
normalization and the top hits for each cell line were
selected based on the SI value of the averaged data. Cor-
relation between experiments was estimated using Pear-
son's correlation coefficient. Statistical analysis was
performed using R software (version 2.10.1).
Cell growth and viability assays
For cell growth assays cells were seeded at 5 × 105 cells
per well of a six-well plate. The next day cells were treated
with 5 μM CCT007093 or 10 nM mithramycin, ± 3 nM
paclitaxel, or vehicle control (DMSO). After three days
cells were collected, washed, and counted using a Coulter
Counter (Beckman-Coulter, Brea, CA, USA). Cell num-
ber was plotted as a percent of cells relative to vehicle
control. Cell viability assays were performed by seeding
3,000 to 8,000 cells per well of a 96-well plate. The next
day, growth media was replaced with treatment media
containing vehicle-DMSO or paclitaxel that was serial
diluted by half-log concentrations ranging from 0.3 to 30
nM. After three days of incubation with the drug, cell via-
bility was measured using the Alamar Blue assay (Invitro-
gen). Cell viability for each drug concentration was
compared to vehicle-treated control. Four replicate wells
from three independent experiments of each drug con-
centration were used to generate median-effect plots to
calculate the IC50 (concentration for 50% growth inhibi-
tion) concentrations for each cell line using Calcusyn
Software (Biosoft, Cambridge, United Kingdom). IC50
values for each cell line are represented with standard
error.
Mammosphere cultures
For three-dimensional (3D) mammosphere cultures, cells
were seeded on growth factor-reduced Matrigel (BD Bio-
sciences, San Jose, CA, USA) in chamber slides as previ-
ously described [51,52]. CCT007093, mithramycin, and
LY2109761 ± paclitaxel were added to medium 24 h after
cell seeding and medium was replaced every three days.
Mammospheres were detached from Matrigel with dis-
pase enzyme (BD Biosciences), trypsinized into single cell
suspensions, and cell number was determined using a
hemocytometer. The number of viable cells was plotted
as a percent of cells relative to vehicle control.
Drug synergy analysis
Paclitaxel was combined with each of the different agents
at a fixed ratio (1:1) of the individual IC50 concentrations
of each drug. Drug combinations were then serial diluted
(1:2) and represented as IC50, IC25, and IC12.5 concentra-
tions, as the additive effects of both drugs. Statistical
analysis of drug synergy was evaluated from the results of
the Alamar Blue assays and calculated using the Chou-
Talaly method [53] and Calcusyn Software (Biosoft). To
determine synergy between two drugs, the software uses
a median-effect method that determines if the drug com-
bination produces greater effects together than expected
from the summation of their individual effects. The com-
bination index (CI) values are calculated for the different
dose-effect plots (for each of the serial dilutions) basedBauer et al. Breast Cancer Research 2010, 12:R41
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on the parameters derived from the median-effect plots
of the individual drugs or drug combinations at the fixed
ratios. The CI was calculated based on the assumption of
mutually nonexclusive drug interactions. CI values signif-
icantly > 1 are antagonistic, not significantly different
than 1 are additive, and values < 1 are synergistic. Two-
sided statistical tests were used to determine if the mean
CI values resulting from three independent experiments
at multiple effect levels were statistically significantly dif-
ferent from a CI = 1.
Results
RNAi screening for genes that sensitize cells to paclitaxel
To identify druggable gene targets that could enhance
paclitaxel activity in breast cancer cells, we performed an
shRNA screen. We selected a subset of genes based on a
comprehensive genomic study of 145 primary human
breast tumors and 51 breast cancer cell lines in which
1,778 gene transcripts were identified whose levels signif-
icantly correlated with genome copy number and are
deemed genomically deregulated in breast cancer [37].
Most of the alterations present in primary tumors were
retained in the cell lines [37]. The 1,778 genomically
deregulated genes were overlaid with a druggable gene
list (compiled from two sources, Open Biosystems and
Qiagen), with the expectation that for select genes identi-
fied in the shRNA screen, an agent may already exist that
could be analyzed in preclinical models for synergistic
activity with paclitaxel. The overlay of the gene lists
yielded 428 genes (Figure 1A). From a whole-genome
v e c t o r - b a s e d  s h R N A m i r  l i b r a r y ,  w e  g e n e r a t e d  a  s u b -
library consisting of 1,078 shRNAs targeting the 428
genes, with 1 to 11 shRNAs per gene. Since the transfec-
tion efficiency of plasmid-based vectors in most breast
cancer cell lines is < 10%, we used a highly transfectable
cell line, HeLa, for our primary screen with the assump-
tion that genes/pathways related to paclitaxel sensitivity
are conserved across cancer cell lines. Positive hits from
the first screen in HeLa cells were validated in secondary
screens using two triple-negative breast cancer (TNBC)
cell lines as described below.
shRNAs for each gene in our sub-library were indepen-
dently transfected into HeLa cells in a 96-well-plate for-
mat and cells were split 24 h after transfection into six
replicate plates. After 48 h, half of the plates (n = 3)
received an IC50 concentration of paclitaxel (5 nM) and
h a l f  r e c e i v e d  v e h i c l e  ( D M S O )  t r e a t m e n t .  I n  o r d e r  t o
detect significant differences in drug sensitivity in the
assay, we allowed time for multiple cell divisions. After
four days of drug treatment, cell viability was measured
using an Alamar Blue assay to identify genes that alter
paclitaxel sensitivity (effect of shRNA and drug). Com-
parison of the mean viability values of three replicates for
each shRNA from the two individual screens revealed
high reproducibility (r = 0.89, Pearson's correlation coef-
ficient) (Figure 1B). We combined the results from the
duplicate screens in the final analyses.
To account for plate-to-plate variability, we normalized
across all the plates using non-silencing (NS) control shR-
NAs that were present in each plate. To identify genes
that when targeted promote paclitaxel sensitivity or resis-
tance; we generated a sensitivity index (SI) score for each
shRNA obtained from replicate experiments after drug
treatment, as previously described (Figure 1C) [32]. The
SI score accounts for the individual effect of shRNAs and
the effect of drug on cell viability. A positive SI score is a
measure of sensitivity and a negative SI score is indicative
of resistance to paclitaxel treatment. In this study, we
chose gene targets that are amplified/overexpressed in
breast and that increase paclitaxel sensitivity (+SI value),
as these are more likely to be better targets for pharmaco-
logical inhibition.
For selection of hits from our primary shRNA screen,
we used a bootstrap algorithm to identify gene targets
that had > 3 shRNAs based on the mean SI > 0.078 (upper
quartile) and the corresponding 95% confidence interval
(Table 1). These criteria allowed for high-confidence hits
to be selected. As the number of positive scoring (+SI)
shRNAs for each gene increased, our confidence for these
genes increased, as these are unlikely due to false-posi-
tives or off-target effects of individual shRNAs. However,
since this method biased our hit selection for those genes
that had more shRNAs in our sub-library, we selected
additional hits represented by genes that had ≤3 shRNAs
but with a much more stringent cutoff of mean SI value >
0.150 (Table 1). FRAP1 (mTOR) (mean SI = 0.212; Table
1) was previously identified through an RNAi screen as a
target of paclitaxel sensitivity, and was used in our screen
as a positive control in each plate [30]. CASP3 shRNA
(mean SI = -0.042) was used as a negative control in each
plate as we found that this gene, when downregulated,
induces paclitaxel resistance (Table 1). Three of the four
shRNAs that target EGFR were highly sensitive to pacli-
taxel activity (mean SI = 0.136, Table 1). EGFR is a known
target of paclitaxel sensitivity as erlotinib, an EGFR inhib-
itor, increases paclitaxel activity in vivo [54-57]. Addition-
ally, TUBG1, tubulin gamma-1, a component of the γ-
tubulin ring complex (γ-TuRC), involved in mitotic spin-
dle formation, enhanced paclitaxel sensitivity (mean SI
value = 0.152, Table 1). γ-TuRC has previously been
shown to enhance paclitaxel sensitivity, in vitro [33].
These data collectively validated our primary shRNA
screening approach.
To determine if the results of the shRNA screen were
reproducible in breast cancer cells, we validated the top
36 high-confidence hits (genes) from the shRNA screen
that were amplified/overexpressed in breast cancer and
had positive SI values (Table 1). Some of the genesBauer et al. Breast Cancer Research 2010, 12:R41
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Figure 1 shRNA screen to identify paclitaxel sensitizers. A. The overlay of druggable genome libraries (Qiagen and Open Biosystems) and genes 
deregulated in breast cancer resulted in 428 candidate druggable genes. B. Reproducibility of shRNA screen by correlation of the effect of shRNAs on 
cell growth compared to non-silencing shRNA in vehicle-treated plates of two replicate experiments. Spearman correlation coefficient, r = 0.89. C. 
Each shRNA was scored for the level of paclitaxel sensitivity using the sensitivity index (SI) as described in Materials and Methods. The SI score ranges 
from -1 to 1. Positive significant SI scores indicate sensitization and negative significant SI scores indicate antagonism. The scatter plot of all shRNAs is 
shown in rank order. The dashed lines indicate the relative threshold of significant drug sensitivity.Bauer et al. Breast Cancer Research 2010, 12:R41
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selected are targets of agents that have not been tested for
efficacy in combination with paclitaxel in the preclinical
setting and are of biological relevance and interest (for
example, transforming growth factor beta (TGFβ) signal-
ing). Two independent siRNA oligos were designed for
each of the 36 genes selected and reverse-transfected into
two TNBC cell lines, MDA-MB-231 and MDA-MB-468.
Duplicate experiments were performed and resulted in
high reproducibility (correlation coefficients approxi-
mately 0.70 to 0.80, data not shown).
We averaged the SI value for the two siRNAs from
duplicate experiments for each gene and the top hits for
each cell line were selected for further analysis (Table 2).
Four genes, PPM1D, CENPF, BCL2L1, and FRAP1 were
sensitizers of paclitaxel in both cell lines (bold, Table 2).
Since paclitaxel efficacy is dependent on mitotic activity
(that is, cell cycle transit into M-phase), we postulated
that siRNAs that decreased cell viability > 30% in
untreated plates were unlikely candidates for enhancing
paclitaxel activity as cell cycle slowing or arrest limits the
efficacy of paclitaxel. However, we did note the effect that
some siRNAs had on breast cancer cell viability in
untreated plates as the targeted gene may be of potential
interest for further investigation for breast cancers that
do not have targeted therapy, such as TNBC. For exam-
ple, IGF1 siRNA in MDA-MB-468 cells led to a 60%
reduction in viability compared to NS siRNA control
(data not shown). However, we did not observe signifi-
cant sensitivity to paclitaxel (SI = -0.031) for IGF1 siR-
NAs in these cells, likely due to the large loss of cell
viability prior to paclitaxel treatment.
To ensure that drug sensitivity correlated with relative
decreases in gene expression and to eliminate any possi-
ble off-target effects from shRNAs and siRNAs, we used
Dharmacon ON-TARGETplus individual and pooled siR-
NAs as a third independent RNAi approach on select
positive hits and our results with PPMID are shown as an
example. ON-TARGETplus siRNAs for a top hit, PPM1D,
were transfected in two breast cancer cell lines, MCF-7
and MDA-MB-468. PPM1D knockdown was measured at
48 h after transfection by quantitative real-time PCR.
Three of the four individual and the pooled ON-TAR-
Table 1: Paclitaxel sensitivity index for indicated genes from shRNA screen
> 3 clones mean SI > 0.078 < 3 clones mean SI > 0.150
Gene shRNAs Mean SI 95% CI Genomic dereg* Gene shRNAs Mean SI Genomic dereg*
YWHAZ 6 0.193 0.154 to 0.242 amp/OE PCK1 1 0.461 amp/OE
RPS6KB1 4 0.186 0.135 to 0.242 amp/OE SREBF2 1 0.391 amp/OE
COG2 5 0.186 0.110 to 0.265 amp/OE SRC 1 0.276 amp/OE
PTK2 5 0.184 0.121 to 0.287 amp/OE FNTA 1 0.263 amp/OE
PPM1D 4 0.179 0.120 to 0.241 amp/OE BCL2L1 1 0.247 amp/OE
SKP1A 6 0.166 0.075 to 0.259 amp/OE COMMD1 3 0.220 amp/OE
MARK1 5 0.157 0.006 to 0.345 amp/OE COG8 1 0.214 amp/OE
NFYB 4 0.148 0.085 to 0.186 amp/OE FRAP1 1 0.212 NA
RBBP4 4 0.139 0.080 to 0.198 amp/OE ERBB2 1 0.180 amp/OE
IL10 4 0.136 0.081 to 0.205 amp/OE IQGAP1 3 0.176 amp/OE
EGFR 4 0.136 0.087 to 0.378 amp/OE PHB 3 0.159 amp/OE
SP1 5 0.130 0.080 to 0.138 amp/OE NDUFS6 1 0.159 amp/OE
STX16 4 0.107 0.053 to 0.175 amp/OE COG1 1 0.159 amp/OE
PTPN7 4 0.095 0.019 to 0.170 amp/OE PRPF4B 3 0.156 amp/OE
SENP1 5 0.095 0.022 to 0.168 amp/OE FADD 3 0.156 amp/OE
CENPF 4 0.085 0.030 to 0.140 amp/OE ERK1 1 0.154 amp/OE
IGF1 4 0.078 0.016 to 0.137 amp/OE TGFB1 1 0.153 amp/OE
TUBG1 3 0.152 amp/OE
CASP3
(control)
5 -0.042 -0.061 to -0.021 del/UE IKBKB 2 0.151 amp/OE
*as determined by DNA copy number and gene expression analysis by Neve et al.
SI, sensitivity index; CI, confidence interval
amp/OE, amplification/overexpressed; del/UE, deletion/underexpressed
NA, not availableBauer et al. Breast Cancer Research 2010, 12:R41
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GETplus siRNAs for PPM1D showed > 80% reduction in
PPM1D mRNA levels in MCF-7 cells and > 60% reduc-
tion in MDA-MB-468 cells (Additional File 2). Impor-
tantly, knockdown of PPM1D was correlated with
increased paclitaxel sensitivity over a range of paclitaxel
doses in both cell lines (Additional File 2). The use of
multiple shRNAs and validation with independent siR-
NAs limited the likelihood that the observed sensitivity
was due to off-target effects.
Candidate pharmacological inhibitors that enhance 
paclitaxel sensitivity
A primary goal of this study was to identify gene targets
that are druggable, to which pharmacological agents have
been developed, and that can be used in novel combina-
tions with paclitaxel in preclinical studies. The list of top
hits from the validation siRNA screen for both cell lines is
shown in Table 2 with associated chemical agents identi-
fied using in silico drug databases (see Materials and
Methods). In some cases, agents linked to genes in the list
represent FDA-approved drugs, some of which have
already been successfully used in combination with pacli-
taxel (for example, FRAP1; rapamycin [58,59], EGFR;
erlotinib [54,60,61]). Gene targets with inhibitors known
to enhance paclitaxel sensitivity both in preclinical [62-
67] and clinical models [54,58,61,68,69] (noted in Table 2)
were not studied further; however, their discovery vali-
dated our RNAi screening approach. We also did not pur-
sue hits that had non-specific inhibitors and those that
had no available agents despite being considered drugga-
ble (for example, MARK1); however, those gene targets
still remain of interest. Since some hits are involved in
intricate signaling pathways, there could be other drug
targetable molecules within the same pathway, which
could impact paclitaxel sensitivity. For example, a top hit
in our screen, RPS6KB1, is downstream of mTOR and
PI3K, two prominent signaling pathways in breast cancer
with known direct inhibitors, rapamycin and LY294002,
and that have been shown to sensitize cells to paclitaxel
[59,70].
Three gene targets from our list were of particular
interest. These genes encode proteins to which agents
have been developed and thus we could test the com-
pounds in combination with paclitaxel for biological
effect. The first was PPM1D, a member of the PP2C fam-
ily of serine/theronine protein phosphatases, and a
known negative regulator of cell stress response pathways
including those regulated by p53, CHEK1, and p38 MAP
kinase [71]. PPM1D is amplified and overexpressed in
breast cancers [72,73] and inhibition of its activity,
through use of small molecules such as CCT007093,
inhibits the growth of tumor cell lines that overexpress
PPM1D [74,75]. The second gene target of interest was
SP1, a constitutively expressed transcription factor that
Table 2: Top gene targets from siRNA screen that increase paclitaxel sensitivity and the corresponding chemical inhibitors
MDA-MB-231 MDA-MB-468 Previous 
combination with 
paclitaxel
Gene Mean
SI
Mean
SI
Drug/chemical inhibitor Pre-
clinical
Clinical Ref
PPM1D 0.055 0.136 thioxanthen-9-one; CCT007093; anti-
estrogens*
no no
CENPF 0.049 0.113 farnesyltransferase inhibitors* yes yes [62,68,69]
BCL2L1 0.041 0.093 ABT-737; AT-101 yes no [63,64]
FRAP1 0.037 0.078 rapamycin; RAD001 yes yes [58,59]
IGF1 0.038 NVP-AEW541; 9-cis-retinoic acid*; 
raloxifene*
yes no [67]
EGFR 0.154 erlotinib; gefitinib; cetuximab yes yes [54,60,61]
ERK1 0.148 ERK/MEK inhibitors yes no [65,66]
RPS6KB1 0.140 rapamycin*; RAD001* yes yes [58,59]
TGFB1 0.121 LY2109761; LY2157299; SD-208 no no
SP1 0.085 mithramycin; arsenic trioxide* no no
*indirect inhibitors
SI, sensitivity indexBauer et al. Breast Cancer Research 2010, 12:R41
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regulates basal promoter activity of many housekeeping
genes. SP1-binding activity has been shown to be higher
in human breast carcinomas than in normal tissues and
may play a role in tumorigenesis by regulating the expres-
sion of genes involved in angiogenesis, cell growth, and
apoptosis resistance [76,77]. Mithramycin A binds to
dsDNA and inhibits SP1 binding sites (GC-rich regions of
promoters) thus inhibiting SP1 transcriptional activity
[78]. Finally, TGFβ1 is a ligand that regulates a signaling
pathway that becomes deregulated in many types of
malignancies including breast cancer [79]. TGFβ1 can act
in a paracrine manner to promote tumor growth and can
activate PI3K/AKT, a signaling program associated with
drug resistance [80]. Thus, the ligand TGFβ1 and its
receptors TGFβ receptor (TGFβR) type I and II have been
pursued as anti-cancer targets. LY2109761 is a small mol-
ecule inhibitor of TGFβR I and II and has been shown to
inhibit tumor cell migration, invasion, as well as sup-
pressing metastasis in vivo [80-82].
Pharmacological agents enhance paclitaxel cell growth 
inhibition of breast cancer cells
To observe potential enhanced activity of drug combina-
tions, < IC50 concentrations of CCT007093 or mithramy-
cin were combined with a < IC50  concentration of
paclitaxel. These combinations resulted in increased
growth inhibition of three breast cancer cell lines tested,
MDA-MB-231, MDA-MB-468, and MCF-7 relative to
single agent treatment (Figure 2A). CCT007093 alone
had little effect on MDA-MB-231 or MDA-MB-468 cell
growth (< 15% inhibition) but significantly decreased
proliferation in combination with paclitaxel, 47% and 55%
inhibition (P < 0.05), respectively. MCF-7 cells, which
contain an amplification of PPM1D [73], are sensitive to
single agent CCT007093 treatment (38% inhibition of cell
growth, Figure 2A) and synergized with paclitaxel result-
ing in a 79% inhibition of cell growth (P < 0.01). Mith-
ramycin in combination with paclitaxel also significantly
inhibited cell growth in the triple-negative MDA-MB-231
and MDA-MB-468 cells relative to the effect observed
when either drug was used alone (P < 0.05). However,
mithramycin treatment of MCF-7 cells failed to enhance
paclitaxel activity greater than the additive effects of
either drug alone (additive effective = 50%, observed
effect = 51%). Of note, we did not observe any appreciable
drug effects on cell viability in 2D cultures with the
TGFβR inhibitor LY2109761, alone or in combination
with paclitaxel in parallel assays with the cell lines
described above (data not shown).
Novel drug combinations with paclitaxel inhibit 3D growth 
of breast cancer cell lines
To determine the effect of the novel drug combinations
on paclitaxel sensitivity in 3D cultures, we grew two cell
lines, MDA-MB-468 and MCF-7, as mammospheres, a
culture method that has been developed to analyze breast
epithelial function, morphology, and invasiveness [51,52].
Paclitaxel treatment alone reduced mammosphere for-
mation and overall cell number by 37% in MCF-7 and
36% in MDA-MB-468 cells (Figure 3A, B). CCT007093
treatment alone reduced MCF-7 mammospheres by 46%
versus < 1% reduction of MDA-MB-468 mammospheres,
a line that does not have appreciable PPM1D expression
levels. However, CCT007093 treatment enhanced pacli-
taxel sensitivity and reduced mammosphere cell number
by 89% in MDA-MB-468 and 92% in MCF-7 cultures.
Likewise, we observed a significant reduction in the num-
ber of cells in the mammospheres that formed with the
combination of mithramycin and paclitaxel in both
MDA-MB-468 and MCF-7 cells (92% and 86% reduction,
respectively). Although we did not observe any apprecia-
ble drug synergy with the TGFβR inhibitor LY2109761 in
2D, monolayer cell culture, we did observe a significant
effect in 3D cultures. When used in combination with
paclitaxel, LY2109761 inhibited mammosphere forma-
tion and reduced cell number by 72% and 92% compared
to control in MDA-MB-468 and MCF-7 cells, respec-
tively; however, it had minimal effect on mammosphere
cell growth when used as a single agent (< 20% reduc-
tion).
CCT007093 and mithramycin synergistically enhance 
paclitaxel activity in paclitaxel-sensitive and -resistance 
TNBC cell lines
There are currently no targeted therapies for patients
with TNBC. Frequently, patients with this type of breast
cancer receive paclitaxel, due to its initial effects and
higher response rates as compared to other chemothera-
pies [83]. However, not all patients have a complete
response and those that are resistant or have residual dis-
ease after initial or secondary chemotherapy have a worse
prognosis and outcome [83,84]. In addition, TNBC
p a t i e n t s  t h a t  i n i t i a l l y  r e s p o n d  t o  c h e m o t h e r a p y  h a v e  a
higher incidence and faster relapse compared to patients
with non-TNBC [85]. Thus, improving the effect of initial
paclitaxel treatment is an important goal in successfully
treating patients with TNBC until more improved and/or
targeted therapies are developed.
Along these lines, we determined the relative paclitaxel
sensitivity of a panel of TNBC cell lines by determining
the paclitaxel IC50 values for 22 TNBC cell lines (Figure
4A). The distribution of IC50 values across the panel led
us to classify 18 cell lines as relatively paclitaxel-sensitive
and four cell lines (CAL120, SW527, HDQP1, and MT3,
which had relatively high IC50 values (> 20 nM)) as rela-
tively paclitaxel-resistant. We determined if the four
resistant cell lines could be sensitized to paclitaxel using
the novel drug combinations presented above andBauer et al. Breast Cancer Research 2010, 12:R41
http://breast-cancer-research.com/content/12/3/R41
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Figure 2 Novel drug combinations sensitize breast cancer cells to paclitaxel. A. MDA-MB-231, MDA-MB-468, and MCF-7 breast cancer cell lines 
were seeded in six-well plates and treated with vehicle (control), < IC50 concentrations of the putative PPM1D inhibitor, CCT007093 (CCT); paclitaxel 
(tax); or a combination of both (CCT + tax). Cells were treated for 72 h, washed, trypsinized and counted. The percent of viable cells relative to control 
was plotted for each drug or combination. B. Same as A with < IC50 concentration the putative SP1-binding inhibitor, mithramycin (mith). Error bars 
represent standard deviation of triplicates from three independent experiments. * indicates P < 0.05, ** indicates P < 0.01.Bauer et al. Breast Cancer Research 2010, 12:R41
http://breast-cancer-research.com/content/12/3/R41
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Figure 3 Analysis of drug combinations on growth of breast cancer cells grown in 3D cultures. A. Cells were seeded on Matrigel in eight-well 
chamber slides as described in Materials and Methods. 3D cultures formed after two days and were treated every two to three days with single agents, 
vehicle (control), 1 nM paclitaxel (tax), 500 nM LY2109761 (LY), 10 μM CCT007093 (CCT), 25 nM mithramycin (mith) (upper panels) or a combination 
of drugs (lower panels). After 10 to 14 days, mammospheres were visualized using phase-contrast microscopy. Bar scale, 50 μm. B. To count cell num-
bers, the Matrigel was dissolved, mammospheres were collected, trypsinized and single cells were counted by trypan blue exclusion assay using a 
hemocytometer. The percent cell number relative to control was plotted for each drug or combination for the two cell lines. Error bars represent stan-
dard deviation from replicates from three independent experiments.Bauer et al. Breast Cancer Research 2010, 12:R41
http://breast-cancer-research.com/content/12/3/R41
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Figure 4 Drug combinations to enhance cell death of TNBC cell lines. A. Twenty-two triple-negative cell lines were each seeded in 96-well plates. 
The next day cells were treated with vehicle control or paclitaxel (0.3 to 30 nM). IC50 values for each cell line were generated based on the median-
effect plot from three independent experiments. IC50 values represent the inhibitor concentration required for a 50% reduction in cell viability relative 
to vehicle-treated controls. Error bars represent standard deviation of four replicates from three independent experiments. B. Cell lines were seeded 
in 96-well plates and treated with single agents (IC50 values) or a combination of drugs (CCT007093 + paclitaxel or mithramycin + paclitaxel) of the 
IC50 concentrations of each drug (1:1 ratio) serial-diluted (IC50-IC25-IC12.5). Combination index (CI) values were calculated using the Chou-Talalay meth-
od with CalcuSyn software (Biosoft). CI values significantly > 1 are antagonistic, not significantly different than 1 are additive, and values < 1 are syn-
ergistic. Error bars represent standard deviation of quadruplicates from three independent experiments.Bauer et al. Breast Cancer Research 2010, 12:R41
http://breast-cancer-research.com/content/12/3/R41
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assayed the two lines used in our RNAi screening, MDA-
MB-231 and MDA-MB-468 for comparison (Figure 4A).
A four-day cell viability assay after combination treat-
ments was used to assess drug synergy, defined as the
combination of two agents that have a greater therapeutic
effect than would be expected by the addition of individ-
ual effects of each drug. The well-established Chou and
Talalay method was used to determine drug synergy, as
described in Materials and Methods [53]. Combination
index (CI) values were derived from the median-effect
plots of single agents alone or in combination and statisti-
cal tests were used to determine whether the CI values at
multiple dose-effect levels (IC50, IC25, IC12.5) were statisti-
cally significantly different from 1 (P < 0.05). CI values
significantly < 1 indicate synergy, not significantly differ-
ent from 1 indicates additive, and a CI value significantly
> 1 indicates antagonism.
CCT007093 was synergistic with paclitaxel (average CI
value significantly < 1, P < 0.05) in two paclitaxel-sensi-
tive cell lines, MDA-MB-468 and MDA-MB-231, average
CI value of 0.56 and 0.38, respectively, and in two of the
four paclitaxel-resistant cell lines CAL120 (average CI =
0.89) and HDQP1 (average CI = 0.65) (Figure 4B).
CCT007093 was additive with paclitaxel in the two other
paclitaxel-resistant cell lines SW527 and MT3 (average
CI values not significantly different than 1 (P > 0.05)).
Mithramycin was synergistic with paclitaxel in the two
paclitaxel-sensitive lines MDA-MB-468 and MDA-MB-
231, average CI value of 0.66 and 0.54, respectively, and
the paclitaxel-resistant cell line HDQP1 average CI value
0.87. However, mithramycin and paclitaxel were antago-
nistic, average CI values significantly > 1, in reducing cell
viability at high effective drug doses (IC50 and IC25) in the
paclitaxel-resistant lines CAL120, SW527 and MT3 (Fig-
ure 4B). Collectively these data indicate that novel drug
combinations with paclitaxel can effectively reduce cell
viability of select paclitaxel-sensitive and importantly,
paclitaxel-resistant TNBC cell lines.
Discussion
Our RNAi screen represents a directed approach to iden-
tifying breast cancer relevant, druggable targets to
enhance drug sensitivity. The screen was validated by our
finding that several of the positive hits are genes that are
known targets of paclitaxel sensitivity and have been clin-
ically targeted in combination with taxanes
[54,58,61,68,69]. We identified additional novel gene tar-
gets and respective agents that were not previously iden-
tified by drug sensitivity RNAi screens or whose
inhibitors were not previously combined with paclitaxel.
We found PPM1D as a target for paclitaxel sensitivity in
our RNAi screens and in follow-up studies observed syn-
ergistic inhibition of tumor cell growth with use of the
PPM1D inhibitor CCT007093 in high PPM1D, wild-type
p53 expressing MCF-7 cells. The oncogenic activity of
PPM1D expression is attributed to its phosphatase activ-
ity and ability to deregulate tumor suppressor genes such
as p53, Chk1, and p38 [71]. PPM1D contributes to the
development of human cancers by suppressing p53 acti-
vation and thus has been an attractive therapeutic target
in tumors that overexpress PPM1D and those with wild-
type functional p53 activity [73]. Indeed, others have
found that suppression of PPM1D expression by RNAi
inhibits proliferation and induces apoptosis in breast can-
cer cell lines with wild-type p53 (BT-474) and those with
PPM1D amplification (MCF-7 and ZR-75-1) [86]. How-
ever, the effect of inhibition of PPM1D on tumor cell
growth and drug sensitivity is not limited to tumor cells
that harbor these amplifications as we observed synergis-
tic or additive activity of CCT007093 with paclitaxel in
TNBC cell lines (MDA-MB-231 and MDA-MB-468,
mutant p53 cell lines) including some paclitaxel-resistant
lines. Likewise, Belova et al. identified chemical com-
pounds that inhibit PPM1D activity and showed that
these compounds could significantly inhibit tumor cell
growth in MCF-7 cells and those with low PPM1D,
mutant p53 expression MDA-MB-231 [74]. Interestingly,
PPM1D inhibitors in both of these cell lines were able to
potentiate the effects of doxorubicin but failed to
enhance activity in other cell lines (MDA-MB-361) [74].
We found that mithramycin, an inhibitor of SP1 bind-
ing, could synergize with paclitaxel in some TNBC
(basal-like) cell lines, MDA-MB-231, MDA-MB-468, and
HDQP1. SP1 is a zinc finger transcription factor impor-
tant in the regulation of genes involved in cell survival,
growth and differentiation, and tumor development and
progression [77]. SP1 cooperates with other prominent
transcription factors including oncogenes such as MYC,
which may contribute to tumor cell proliferation and
growth [87,88]. MYC has recently been shown to have
elevated activity and gene signatures present in basal-like
TNBCs [89,90]. Thus, inhibiting SP1 binding with mith-
ramycin may block oncogenic transcriptional activity and
cooperate with anti-mitotic agents such as paclitaxel to
inhibit tumor cell growth. In addition, SP1 is a potent
transactivator of IGF-IR and EGFR, two prominent genes
overexpressed in breast cancer cells (for example, MDA-
MB-468) and both of which were identified as hits in our
screen [91,92].
Despite extensive preclinical studies aimed at therapeu-
tically targeting the TGFβ signaling pathway, there is a
lack of reports in which TGFβ inhibitors are combined
with paclitaxel. We found that the TGFβR inhibitor
LY2109761 is synergistic with paclitaxel in breast cancer
cells grown in 3D cultures but not 2D cultures, indicating
the importance of performing drug combination in more
than one growth context. TGFβ protects mammary epi-
thelial cells from apoptosis in the absence of serum,Bauer et al. Breast Cancer Research 2010, 12:R41
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which may be through activation of the PI3K/AKT cell
survival pathway [80,93]. Thus, inhibition of TGFβ may
sensitize cells that are grown in low-serum and/or
anchorage-independent 3D conditions to apoptosis-
inducing agents like paclitaxel. In support of this, others
have shown that inhibition of TGFβ in human breast car-
cinoma cells grown in 3D cultures that secrete high levels
of TGFβ increases the cytotoxic response to ionizing
radiation and several chemotherapeutic drugs, namely
cisplatin [94]. Likewise, inhibition of TGFβ can prevent
radiation-induced acceleration of metastatic cancer pro-
gression [95,96]. On the contrary, Ahmed et al. showed
that the loss of the ECM protein TGFβI is sufficient to
induce specific resistance to paclitaxel and mitotic spin-
dle abnormalities in ovarian cancer cells [97]. In ovarian
and breast tumor specimens, TGFβI expression was
shown to be tightly co-regulated with other genes that
induce paclitaxel sensitivity, such as the adhesion glyco-
protein, THBS1 [97].
The mechanism by which inhibition of TGFβ signaling
cooperates with paclitaxel is not well understood. Intrac-
ellular TGFβ signaling proteins Smad2 and Smad3 bind
microtubules, and upon TGFβ stimulation, these tran-
scription factors dissociate from microtubules, are phos-
phorylated and relocate to the nucleus [98]. TGFβ
signaling may serve as a growth promoter and/or
enabling changes in tumor cell adhesion, migration, and
host-tumor interactions [99]. Thus, loss of TGFβ signal-
ing may sensitize cells to paclitaxel, an agent that can also
alter adhesion and migration due to significant changes in
microtubule dynamics that are required for these biologi-
cal activities.
The ever-increasing volume of genomic information
paired with bioinformatic and biostatistical analyses is
making genotype-driven health care a reality. The tre-
mendous amount of tumor-derived genomic information
available now, and after completion of several large-scale
cancer sequencing efforts, combined with biological vali-
dation of mutations to determine relevant drivers, will
allow for much more facile identification of new targets
for drug discovery, as well as more precise alignment of
patients with a particular targeted therapy. Validation of
putative drug targets through loss-of-function screening,
similar to that performed herein, will likely be a fre-
quently used approach to generate requisite pre-clinical
data to investigate novel single agent and drug combina-
tions. The exciting challenge ahead of us is to integrate
the ever-expanding genomic information as quickly as
possible for human benefit.
Conclusions
We used a genomic-based approach that included loss-
of-function RNAi screening to identify druggable targets
involved in paclitaxel sensitivity in breast cancer cells. We
identified pharmacological agents that target hits from
our screens, several which sensitized breast cancer cells
to paclitaxel. A potential translation of our discoveries is
new treatment options for patients with TNBC disease,
those without current clinically proven targeted thera-
pies. In summary, we provide a platform in which inte-
grated genomic information can be rationally used to
design functional screens to identify druggable targets to
improve current treatments or to discover novel cancer
treatment strategies.
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